Abelacimab
mAbexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Oct 3, 2018 (NCT03393481)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
Coagulation factor XI inhibitor
Binds Factor XI and Factor XIa
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650369 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05712200 | Phase 3 | Dec 27, 2022 | Anthos Therapeutics, Inc. |
| NCT05171075 | Phase 3 | Sep 27, 2022 | Anthos Therapeutics, Inc., Itreas |
| NCT05171049 | Phase 3 | May 5, 2022 | Anthos Therapeutics, Inc., Itreas |
| NCT04755283 | Phase 2 | Feb 2, 2021 | Anthos Therapeutics, Inc., Covance, The TIMI Study Group |
| NCT04213807 | Phase 2 | Dec 11, 2019 | Anthos Therapeutics, Inc., Covance |
| NCT03398434 | Phase 2 | Oct 16, 2018 | Novartis |
| NCT03393481 | Phase 2 | Oct 3, 2018 | Novartis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anthos Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2019 |
| Covance | For profit | 2 | 0 | 1 | 2019 |
| Itreas | For profit | 2 | 0 | 1 | 2022 |
| Novartis | For profit | 2 | 2 | 1 | 2018 |
| The TIMI Study Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1